Drug Trial Radar · NCT06787586
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
108
Actual
Start
Jan 14, 2025
Primary completion
Jun 11, 2026
Study completion Jun 11, 2026
Sponsor
- Lead sponsor
- Attovia Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310? How long does ATTO-1310 stay in the body after dosing? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Conditions
- Normal Volunteers
- Atopic Dermatitis (AD)
- Atopic Eczema
- Chronic Pruritus
Interventions
ATTO-1310Drug
ATTO-1310 Attobody
ATTO-1310 PlaceboDrug
Placebo preparation to match ATTO-1310 Dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AEsTime frame: 0-113 Days for SAD; 0-143 Days for MAD
- Incidence of laboratory abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD
- Incidence of ECG abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD
- Incidence of vital sign abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Attovia Clinical Site 103
Encinitas, California
Attovia Clinical Site 116
Rocklin, California
Attovia Clinical Site 107
Sacramento, California
Attovia Clinical Site 109
Coral Gables, Florida
Attovia Clinical Site 118
Margate, Florida
Attovia Clinical Site 102
Plainfield, Indiana
Attovia Clinical Site 104
Saint Joseph, Missouri
Attovia Clinical Site 106
Reno, Nevada
Attovia Clinical Site 114
New York, New York
Attovia Clinical Site 119
New York, New York
Attovia Clinical Site 108
San Antonio, Texas
Attovia Clinical Site 110
Fredericton, New Brunswick, Canada
Attovia Clinical Site 111
Newmarket, Ontario, Canada
Attovia Clinical Site 112
Peterborough, Ontario, Canada
Attovia Clinical Site 113
Toronto, Ontario, Canada
Attovia Clinical Site 105
Montreal, Quebec, Canada
Altasciences
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.